Effect of Gut Microbiota & Fecal Inflammatory Marker on Childhood

Status Completed

Clinical Trial Summary

Childhood gastroenteritis establishes gastrointestinal disease and increase the economic burden, and the pediatric population is especially vulnerable to these gastrointestinal infections. The aim of this study is to evaluate the role of intestinal microbiota and their relationship with childhood gastroenteritis.

Clinical Trial Description

Childhood gastroenteritis establishes gastrointestinal disease and increase the economic burden, and the pediatric population is especially vulnerable to these gastrointestinal infections. According to a World Health Organization report in 2003, the median incidence of diarrhea for all children age under 5 years was 3.2 episodes per child-year, and this number has not changed significantly since 1980s. In Taiwan, the enteric pathogens associated mortality is low, but the social burden and economic costs are substantial because of the high incidence.

Intestinal microflora are able to use the substances consumed in the diet: bacteria can transform complex polysaccharides and monosaccharides in short-chain fatty acids. Short-chain fatty acids are a source of energy for colonocytes and directly affect the storage of lipids and the absorption and metabolism of food, creating the so-called 'second meal effect'.

Qualitative and quantitative alterations of commensal flora may result in various gastrointestinal and extraintestinal diseases. One of the first interactions these bacteria have when interacting with the intestinal epithelial cells lining the GI tact.

The first aim of this study is to evaluate the role of intestinal microbiota and their relationship with childhood gastroenteritis. The second aim of this study is determining the inflammatory markers (such as fecal TNF-α, interleukin -6, calprotectin, lactoferrin) on the host of childhood gastroenteritis. The investigators try to seek to gain an advanced understanding effect of intestinal microbiota and fecal inflammatory marker in the childhood gastroenteritis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03856138
Study type	Observational
Source	Chang Gung Memorial Hospital
Contact
Status	Completed
Phase
Start date	December 1, 2015
Completion date	February 28, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04496154` - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood	N/A
Not yet recruiting	`NCT06434701` - Severe COVID-19 Infection in Children Presenting to EDs in Israel and England	N/A
Enrolling by invitation	`NCT05020210` - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed	`NCT04084301` - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury	N/A
Completed	`NCT04597983` - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists	N/A
Not yet recruiting	`NCT06016023` - Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
Not yet recruiting	`NCT05990933` - Role of Adrenaline in in the Inflammatory Response in Diabetes	N/A
Not yet recruiting	`NCT04608643` - Inflammatory Markers and Cbc Indices in Severely Malnourished Children
Recruiting	`NCT01934049` - Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty	Phase 4
Recruiting	`NCT01417923` - The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain	Phase 4
Terminated	`NCT01377441` - Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.	Phase 4
Completed	`NCT01301079` - Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia	Phase 3
Terminated	`NCT00578578` - Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels	Phase 4
Recruiting	`NCT04611334` - The Effects of HRV Biofeedback on Chronic Kidney Disease Patient.	N/A
Recruiting	`NCT03510702` - SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
Completed	`NCT03445234` - Blueberries, Bananas, Exercise Recovery	N/A
Not yet recruiting	`NCT06450704` - Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders	N/A
Not yet recruiting	`NCT05754294` - Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery.
Completed	`NCT04864600` - CANDLE - A Study of Acute Health Effects of Exposure to Particles Generated by Candles	N/A
Not yet recruiting	`NCT04386525` - Omega 3 and Ischemic Stroke; Fish Oil as an Option	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Gut Microbiota and Fecal Inflammatory Marker on Childhood Gastroenteritis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms